H

ello, everyone, and how are you today? We are doing just fine, thank you, especially as we are helped along by a bright, shiny sun enveloping the serene Pharmalot campus. Our shortest person has left for the local schoolhouse and the official mascots are sunning themselves in the parlor. As for us, we are as busy as ever, foraging for interesting items. Speaking of which, here are a few. Hope you have a lovely day and do keep in touch …

Hanmi Pharmaceutical belatedly reported a fatal side effect in a patient during clinical trials of its lung cancer drug Olita Tab, the Korea Herald tells us. The Board of Audit and Inspection of Korea said the drug maker broke two medical laws regarding the monitoring and reporting of its clinical trials. The board had opened an investigation after some lawmakers charged Hanmi of intentionally delaying reporting to win approval for the drug.

This is a STAT Plus article and is only available to STAT Plus subscribers.
To read the full story, subscribe to STAT Plus or log in to your account.
Good news: your first 30 days are on us.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine